Skip to main content

Table 1 Baseline characteristics of the patients

From: Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial

Characteristic Placebo WJMSCs P value
  (n = 58) (n = 58)  
Risk factor    
Age (years) 56.7±1.7 57.3±1.3 0.79
Men - number (%) 51(87.9) 55(94.8) 0.18
Body-mass index (kg/m2) 25.4±0.3 24.9±0.3 0.26
Diabetes mellitus - number (%) 14(24.1) 17(29.3) 0.52
Hyperlipidemia - number (%) 22(37.9) 21(36.2) 0.84
Hypertension - number (%) 26(44.8) 33(56.9) 0.19
Smoking (current of former) -number (%) 32(55.2) 34(58.6) 0.70
Family history of coronary heart disease - number (%) 20(34.5) 17(29.3) 0.55
Coronary artery disease - number (%)    0.19
 1-Vessel disease 28(48.3) 21(36.2)  
 2-Vessel disease 16(27.6) 14(24.1)  
 3-Vessel disease 14(24.1) 23(39.7)  
Infarct treatment
Infarct-related artery - number (%)    0.55
Left anterior descending artery 31(53.4) 29(50.0)  
Left circumflex artery 6(10.3) 10(17.2)  
Right coronary artery 21(36.2) 19(32.8)  
PCI for additional stenoses in non-infarct-related vessels - number (%) 10(17.2) 15(25.9) 0.25
Time from symptom onset to first reperfusion therapy-hour    
Mean 7.3±0.5 7.2±0.5 0.81
Median 6.3 7.3  
Drug-eluting stent - number (%) 58(100) 58(100) 1
Gp II b/IIIa inhibitor during acute PCI - number (%) 7(12.1) 8(13.8) 0.78
Intravenous catecholamines - number (%) 3(5.2) 4(6.9) 0.69
Maximal creatine kinase (U/L) 1899±273 1653±206 0.93
Maximal creatine kinase MB (U/L) 192±21 170±17 0.42
Maximal troponin T (μg/L) 18.2±3.1 24.7±4.1 0.61
TIMI flow grade
Before PCI - number (%)    0.93
 Grade 0 or 1 42(72.4) 42(72.4)  
 Grade 2 8(13.8) 7(12.1)  
 Grade 3 8(13.8) 9(15.5)  
After PCI - number (%)    0.55
 Grade 0 or 1 0(0) 0(0)  
 Grade 2 1(1.7) 2(3.4)  
 Grade 3 57(98.3) 56(96.6)  
Baseline quantitative measure of LV function
Global left ventricular ejection fraction (%)
 Mean 51.1±1.0 52.0±0.9 0.51
Left venticular fractional shortening (%)
 Mean 26.4±0.6 27.2±0.6 0.33
Wall motion score index (17-segment model)
 Mean 1.28±0.03 1.29±0.02 0.62
End-systolic volume (ml)
 Mean 64.6±2.8 63.3±2.7 0.68
End-diastolic volume (ml)
 Mean 129.9±3.5 130.4±3.6 0.90
Cell therapy
Time from reperfusion to infusion of study therapy-days
 Mean 6.3±0.1 6.1±0.1 0.25
 Median 6.5 6.0  
TIMI flow grade before study therapy
 Mean 2.98±0.02 2.97±0.02 0.56
 Median 3 3  
TIMI flow grade after study therapy
 Mean 2.98±0.02 2.97±0.02 0.56
 Median 3 3  
Current medication - number (%)
 Aspirin and clopidogrel 58(100) 58(100) 1
 Beta-blocker 48(82.8) 42(72.4) 0.18
 ACE-inhibitors or angiotensin-receptor B 43(74.1) 42(72.4) 0.83
 Stains 54(93.1) 54(93.1) 1
  1. Data are means (SE) or number (%) unless otherwise stated. TIMI trial grades are defined as follows: grade 0, no perfusion; grade 1, penetration without perfusion; grade 2, partial perfusion; and grade 3, complete perfusion. ACE angiotensin-converting enzymes, LV left ventricular, PCI percutaneous coronary intervention